KinaseNET

Nomenclature

Short Name:

SYK

Full Name:

Tyrosine-protein kinase SYK

Alias:

DKFZp313N1010
EC 2.7.10.2
Spleen tyrosine kinase
SYK
FLJ25043
FLJ37489
Kinase Syk
KSYK

Classification

Type:

Protein-tyrosine kinase

Group:

Family:

Syk

SubFamily:

Specific Links

BioCarta Entry:	bcr pathway
Entrez-Gene Entry:	6850
Entrez-Protein Entry:	NP_003168
GeneCards Entry:	SYK
KinBASE Entry:	SYK
OMIM Entry:	600085
Pfam Entry:	P43405
PhosphoNET Entry:	P43405
Phosphosite Plus Entry:	662
Protein Data Bank Entry:	1A81
ScanSite Entry:	P43405
Source Entry:	SYK
UCSD-Nature Entry:	A000040
UniProt Entry:	P43405
Kinexus Products:	SYK Spleen protein-tyrosine kinase Y323 phosphosite-specific antibody AB-PK821 Spleen protein-tyrosine kinase Y525+Y526 phosphosite-specific antibody AB-PK823 SykSubtide - Syk protein kinase substrate peptide - Powder PE-01BJM85 Spleen protein-tyrosine kinase (F320-E326, human) pY323 phosphopeptide - Powder PE-04ALE99 Spleen protein-tyrosine kinase (E349-P355, human) pY352 phosphopeptide - Powder PE-04APT99 Spleen protein-tyrosine kinase (D522-Q529, human) pY525+pY526 phosphopeptide - Powder PE-04APU95 Spleen protein-tyrosine kinase (D522-K533, human) pY525+pY526+pT530 phosphopeptide - Powder PE-04AXF95

General Links

Structure

Mol. Mass (Da):

72,066

# Amino Acids:

635

# mRNA Isoforms:

mRNA Isoforms:

72,066 Da (635 AA; P43405); 69,510 Da (612 AA; P43405-2)

4D Structure:

Interacts with RHOH, GAB2 and with NFAM1 (phosphorylated form). Interacts (via its SH2 domains) with CD79A (via its phosphorylated ITAM domain); the interaction stimulates SYK autophosphorylation and activation By similarity. Interacts (phosphorylated form) with SLA; the interaction may link it to CBL, leading to its destruction. Interacts with Epstein-Barr virus LMP2A. Interacts with FCRL3. Interacts (via the second SH2 domain) with USP25 (via C-terminus).

1D Structure:

Retrieve Gene Sequence
Retrieve Full Protein Sequence
Retrieve Catalytic Domain Sequence

3D Image (rendered using PV Viewer):

PDB ID

4FL1

Subfamily Alignment

Domain Distribution:

Start	End	Domain
15	107	SH2
168	259	SH2
371	628	TyrKc
371	631	Pkinase

Kinexus Products

Click on entries below for direct links to relevant products from Kinexus for this protein kinase.

hiddentext

○	Spleen protein-tyrosine kinase Y323 phosphosite-specific antibody AB-PK821
○	Spleen protein-tyrosine kinase Y525+Y526 phosphosite-specific antibody AB-PK823
○	SykSubtide - Syk protein kinase substrate peptide - Powder PE-01BJM85
○	Spleen protein-tyrosine kinase (F320-E326, human) pY323 phosphopeptide - Powder PE-04ALE99
○	Spleen protein-tyrosine kinase (E349-P355, human) pY352 phosphopeptide - Powder PE-04APT99
○	Spleen protein-tyrosine kinase (D522-Q529, human) pY525+pY526 phosphopeptide - Powder PE-04APU95
○	Spleen protein-tyrosine kinase (D522-K533, human) pY525+pY526+pT530 phosphopeptide - Powder PE-04AXF95

Post-translation Modifications

For detailed information on phosphorylation of this kinase go to PhosphoNET

Acetylated:

K105, K116, K394, K402, K571.

Serine phosphorylated:

S178, S202, S295, S297, S316, S319, S350, S579.

Threonine phosphorylated:

T73-, T161, T345, T504, T530.

Tyrosine phosphorylated:

Y28, Y47, Y74, Y91, Y131-, Y203, Y244, Y296, Y323+, Y348+, Y352+, Y431, Y507, Y525+, Y526+, Y539, Y546, Y568, Y629, Y630, Y631.

Ubiquitinated:

K60, K509, K517.

Distribution

Based on gene microarray analysis from the NCBI

Human Tissue Distribution

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

100

1393

41

1286
1.1

15

19

11
23

320

14

308
21

286

154

1008
56

777

43

547
4

49

94

48
25

346

59

536
92

1287

51

3097
47

648

17

543
10

133

162

161
6

87

38

160
41

576

235

628
31

430

36

688
0.5

7

11

7
9

127

37

173
2

28

26

23
10

140

360

1684
19

268

25

354
3

41

137

57
45

627

165

552
16

218

33

339
33

465

39

620
20

278

24

374
17

234

26

665
35

487

35

641
67

928

100

852
35

489

38

680
15

207

26

306
10

141

25

200
7

100

56

93
26

363

24

369
49

687

46

658
22

312

96

331
90

1249

109

901
11

148

61

203

Evolution

Species Conservation

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:

100

100

100
85.5

85.7

95
99.1

99.5

99
-

-

93
-

-

92
91.2

94.4

93
-

-

-
92.1

94.5

93
91

93.7

92
-

-

-
-

-

-
77.5

87.4

81
67.7

79.1

-
66

77.5

72
-

-

-
25.6

39.9

-
-

-

-
-

-

-
26.5

40.7

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-
-

-

-

For a wider analysis go to PhosphoNET Evolution in PhosphoNET

Binding Proteins

Examples of known interacting proteins

hiddentext

No.	Name – UniProt ID
1	CBL - P22681
2	VAV1 - P15498
3	FCGR2A - P12318
4	PTPN6 - P29350
5	CBLB - Q13191
6	CD79B - P40259
7	BLNK - Q8WV28
8	POU2AF1 - Q16633
9	CD22 - P20273
10	HCLS1 - P14317
11	DBNL - Q9UJU6
12	SLC4A1 - P02730
13	CSF2RB - P32927
14	TUBA4A - P68366
15	MS4A2 - Q01362

Regulation

Activation:

Phosphorylation of Tyr-348 and Tyr-352 enhances the binding, phosphorylation and activation of phospholipase C-gamma and the early phase of Ca(2+) mobilization via a phosphoinositide 3-kinase-independent pathway. Phosphorylation of Tyr-525 and Tyr-526 increases phosphotransferase activity.

Inhibition:

Phosphorylation of Tyr-131 inhibits interaction with Bcr. Phosphorylation of Tyr-323 negatively regulates B cell Ag receptor signaling and strongly dampens the Ca(2+) signal.

Synthesis:

Degradation:

Known Upstream Kinases

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.

Based on in vitro and/or in vivo phosphorylation data

Kinase Short Name	UniProt ID (Human)	Phosphosite Location	Phosphosite Sequence	Effect of Phosphorylation

SYK	P43405	Y131	KENLIREYVKQTWNL	-
SYK	P43405	Y323	STVSFNPYEPELAPW	+
LCK	P06239	Y323	STVSFNPYEPELAPW	+
LYN	P07948	Y323	STVSFNPYEPELAPW	+
SYK	P43405	Y348	LPMDTEVYESPYADP	+
LCK	P06239	Y348	LPMDTEVYESPYADP	+
LYN	P07948	Y348	LPMDTEVYESPYADP	+
SYK	P43405	Y352	TEVYESPYADPEEIR	+
LCK	P06239	Y352	TEVYESPYADPEEIR	+
LYN	P07948	Y352	TEVYESPYADPEEIR	+
SYK	P43405	Y525	ALRADENYYKAQTHG	+
SYK	P43405	Y526	LRADENYYKAQTHGK	+

Known Downstream Substrates

For further details on these substrates click on the Substrate Short Name or UniProt ID. Phosphosite Location is hyperlinked to PhosphoNET predictions.

Based on in vitro and/or in vivo phosphorylation data

Substrate Short Name	UniProt ID (Human)	Phosphosite Location	Phosphosite Sequence	Effect of Phosphorylation

BLNK	Q8WV28	Y178	LLEDEADYVVPVEDN	+
BLNK	Q8WV28	Y189	VEDNDENYIHPTESS	+
BLNK	Q8WV28	Y72	SDDFDSDYENPDEHS	+
BLNK	Q8WV28	Y84	EHSDSEMYVMPAEEN	+
BLNK	Q8WV28	Y96	EENADDSYEPPPVEQ	+
Btk	Q06187	Y551	RYVLDDEYTSSVGSK	+
Cbl	P22681	Y700	EGEEDTEYMTPSSRP
Cbl	P22681	Y731	QQIDSCTYEAMYNIQ
Cbl	P22681	Y774	SENEDDGYDVPKPPV
DUSP3 (VHR)	P51452	Y138	SPTLVIAYLMMRQKM	+
DUSP3 (VHR)	P51452	Y38	NEVTPRIYVGNASVA
FcGR2A	P12318	Y281	LEETNNDYETADGGY
FcGR2A	P12318	Y304	TDDDKNIYLTLPPND
FcGR2C	P31995	Y287	PEETNNDYETADGGY
FcGR2C	P31995	Y310	TDDDKNIYLTLPPND
GCET2	Q8N6F7	Y107	GNSAEEYYENVPCKA
GCET2	Q8N6F7	Y128	LGGTETEYSLLHMPS
HCA59 (C9orf78)	Q9NZ63	Y147	KNAEDCLYELPENIR
HPK1 (MAP4K1)	Q92918	Y381	SESSDDDYDDVDIPT	+
HS1	P14317	Y378	EPEPENDYEDVEEMD
HS1	P14317	Y397	EDEPEGDYEEVLEPE	+
ICLN (CLNS1A)	P54105	Y214	TEDSIRDYEDGMEVD
IL15R alpha	Q13261	Y227	AVSLLACYLKSRQTP
ITGB3	P05106	Y773	DTANNPLYKEATSTF
ITGB3	P05106	Y785	STFTNITYRGI____
LAB	Q9GZY6	Y136	EDDDANSYENVLICK
LAB	Q9GZY6	Y193	EDEESEDYQNSASIH
LAB	Q9GZY6	Y233	EEDGEPDYVNGEVAA
LAT	O43561	Y200	SMESIDDYVNVPESG
LAT	O43561	Y220	SLDGSREYVNVSQEL
LCP2	Q13094	Y113	SSFEEDDYESPNDDQ	+
LCP2	Q13094	Y128	DGEDDGDYESPNEEE	+
LCP2	Q13094	Y145	PVEDDADYEPPPSND	+
MAPRE1	Q15691	Y124	ANYDGKDYDPVAARQ
NEK9	Q8TD19	Y520	GLDSEEDYYTPQKVD
NUCKS1	Q9H1E3	Y26	SDDADEDYGRDSGPP
PIK3AP1 (BCAP)	Q6ZUJ8	Y195	CGAETTVYVIVRCKL
PIK3AP1 (BCAP)	Q6ZUJ8	Y419	GEEADAVYESMAHLS
PIK3AP1 (BCAP)	Q6ZUJ8	Y444	PGCDEDLYESMAAFV
PIK3AP1 (BCAP)	Q6ZUJ8	Y459	PAATEDLYVEMLQAS
PKCa (PRKCA)	P17252	Y657	SDFEGFSYVNPQFVH
PKCb (PRKCB)	P05771	Y662	NEFAGFSYTNPEFVI
PLCG1	P19174	Y771	IGTAEPDYGALYEGR
PLCG1	P19174	Y783	EGRNPGFYVEANPMP	+
PLCG2	P16885	Y759	LYDVSRMYVDPSEIN	+
POU2AF1 (BOB1)	Q16633	Y245	EEEDSDAYALNHTLS
RHBG	Q9H310-6	Y429	SPPDSQHYEDQVHWQ
SH3BP2 (3BP2)	P78314	S225	SDMPRAHSFTSKGPG
SH3BP2 (3BP2)	P78314	S278	PATPRRMSDPPLSTM
SH3BP2 (3BP2)	P78314	Y174	YPTDNEDYEHDDEDD
SH3BP2 (3BP2)	P78314	Y183	HDDEDDSYLEPDSPE	+
SH3BP2 (3BP2)	P78314	Y448	GDDSDEDYEKVPLPN	+
SLC4A1	P02730	Y21	ENLEQEEYEDPDIPE
SLC4A1	P02730	Y359	AKPDSSFYKGLDLNG
SLC4A1	P02730	Y8	MEELQDDYEDMMEEN
SLC4A1	P02730	Y904	EEEGRDEYDEVAMPV
SNCA	P37840	Y125	VDPDNEAYEMPSEEG
SNCA	P37840	Y133	EMPSEEGYQDYEPEA
SNCA	P37840	Y136	SEEGYQDYEPEA___
STAT5A	P42229	Y964	LAKAVDGYVKPQIKQ
Syk	P43405	Y131	KENLIREYVKQTWNL	-
Syk	P43405	Y323	STVSFNPYEPELAPW	+
Syk	P43405	Y348	LPMDTEVYESPYADP	+
Syk	P43405	Y352	TEVYESPYADPEEIR	+
Syk	P43405	Y525	ALRADENYYKAQTHG	+
Syk	P43405	Y526	LRADENYYKAQTHGK	+
Tau	P10636	Y17	MEDHAGTYGLGDRKD
TUBA1A	Q71U36	Y432	MAALEKDYEEVGVDS

Protein Kinase Specificity

Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites

Matrix Type:

Experimentally derived from alignment of 64 known protein substrate phosphosites and 41 peptides phosphorylated by recombinant Syk in vitro tested in-house by Kinexus.

Domain #:

Inhibitors

For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's

Based on in vitro and/or in vivo phosphorylation data

Compound Name	KD, Ki or IC50 (nM)	PubChem ID	ChEMBL ID	PubMed ID

Staurosporine	IC50 = 100 pM	5279		19397322
CHEMBL1684800	IC50 = 1 nM	52938983	1684800	21353571
TTT-3002	IC50 < 6 nM
Lestaurtinib	Kd = 9.5 nM	126565		22037378
AC1NS4N8	IC50 = 14 nM	5353854	101797	18077363
Syk Inhibitor	IC50 = 14 nM	6419747	104279	12941345
CHEMBL249097	IC50 = 26 nM	25138012	249097	17600705
Staurosporine aglycone	IC50 < 40 nM	3035817	281948
Syk Inhibitor II	IC50 = 41 nM	16760670		15990316
K-252a; Nocardiopsis sp.	IC50 > 50 nM	3813	281948	22037377
Bosutinib	IC50 = 52 nM	5328940	288441	19039322
CHEMBL1240703	Kd = 64 nM	52945601	1240703	19654408
2hiw	EC50 = 71 nM	10062694		18077425
N-Benzoylstaurosporine	Kd = 88 nM	56603681	608533	18183025
Amgen TBK 1 inhibitor (Compound II)	IC50 = 100 nM
AT9283	IC50 > 100 nM	24905142		19143567
R406	IC50 = 100 nM	11984591
Cdk1/2 Inhibitor III	IC50 > 150 nM	5330812	261720	22037377
Gö6976	IC50 > 150 nM	3501	302449	22037377
SB218078	IC50 > 150 nM	447446	289422	22037377
SureCN373973	Kd < 150 nM	9818573	30678	19035792
SureCN5235694	IC50 = 200 nM	11785878	410295	18278858
Syk Inhibitor IV	IC50 = 200 nM	10200390
IDR E804	IC50 > 250 nM	6419764	1802727	22037377
TWS119	IC50 > 250 nM	9549289	405759	22037377
Foretinib	Kd = 280 nM	42642645	1230609	22037378
GSK-3 Inhibitor IX	IC50 < 400 nM	5287844	409450
PD173955	Kd = 410 nM	447077	386051	22037378
Aloisine A	IC50 = 500 nM	5326843	75680	22037377
Aloisine; RP106	IC50 = 500 nM	44350092	126343	22037377
Alsterpaullone	IC50 = 500 nM	5005498	50894	22037377
TG101209	IC50 = 500 nM	16722832		17541402
AST-487	Kd = 600 nM	11409972	574738	18183025
K00596a	IC50 < 600 nM	9549298	200027
KW2449	Kd = 670 nM	11427553	1908397	22037378
Momelotinib	IC50 < 750 nM	25062766		19295546
BX795	IC50 < 800 nM	10077147	577784
CHEMBL307152	IC50 < 800 nM	11655119	307152	12824014
SureCN3470757	IC50 < 800 nM	11588244	375236
CHEMBL383899	IC50 = 887 nM	9549303	383899	18077363
BX517	IC50 > 900 nM	11161844	228654
Alsterpaullone; 2-Cyanoethyl	IC50 > 1 µM	16760286	260138	22037377
ALX-270-403-M001	IC50 > 1 µM			22037377
Dasatinib	IC50 > 1 µM	11153014	1421	22037377
Dovitinib	IC50 > 1 µM	57336746		22037377
Gö6983	IC50 > 1 µM	3499	261491	22037377
GSK-3 Inhibitor XIII	IC50 > 1 µM	6419766	359482	22037377
GSK-3b Inhibitor XI	IC50 > 1 µM	10020713	272629	22037377
IKK-2 Inhibitor IV	IC50 > 1 µM	9903786	257167	22037377
Indirubin-3′-monoxime	IC50 > 1 µM	5326739		22037377
IPA-3	IC50 < 1 µM	521106	472940
MK5108	IC50 > 1 µM	24748204		20053775
NU6140	IC50 > 1 µM	10202471	1802728	22037377
Ponatinib	IC50 > 1 µM	24826799		20513156
Silmitasertib	IC50 > 1 µM	24748573		21174434
SNS314	IC50 > 1 µM	16047143	514582	18678489
SU11652	IC50 > 1 µM	24906267	13485	22037377
Wyeth PDK1 Inhibitor Compound 1	IC50 = 1 µM
WZ3146	Kd > 1 µM	44607360		20033049
WZ4002	Kd > 1 µM	44607530		20033049
Pelitinib	Kd = 1.2 µM	6445562	607707	15711537
Hesperadin	Kd < 1.25 µM	10142586	514409	19035792
JNJ-7706621	Kd = 1.3 µM	5330790	191003	18183025
NVP-TAE684	Kd = 1.3 µM	16038120	509032	22037378
Tozasertib	Kd = 1.8 µM	5494449	572878	18183025
Crizotinib	Kd = 2.5 µM	11626560	601719	22037378
Pyrrolo-pyrimidone; 17	IC50 = 2.5 µM	16119021	461140	18945615
SureCN5302803	Kd > 2.5 µM	24788740		19035792
Syk Inhibitor III	IC50 = 2.5 µM	672296	596380	16837624
TG101348	Kd = 2.7 µM	16722836	1287853	22037378
Doramapimod	IC50 > 3 µM	156422	103667
KIN 112	IC50 > 3 µM
Ruboxistaurin	IC50 > 3 µM	153999	91829
SureCN4875304	IC50 > 3.5 µM	46871765		20472445
CHEMBL493169	Ki > 4 µM	44219632	493169	19414255
CHEMBL494221	Ki > 4 µM	5328125	494221	19414255
GSK650394A	IC50 < 4 µM	25022668	558642
JNJ-28871063	IC50 > 4 µM	17747413		17975007
Pyrimidylpyrrole, 11e	Ki > 4 µM	11634725	583042	19827834
BMS-690514	IC50 = 4.3 µM	11349170		21531814
RAF265	Kd = 4.4 µM	11656518	558752	22037378
(5Z)-7-Oxozeaenol	IC50 > 4.5 µM		1077979
GSK429286	IC50 > 4.5 µM	11373846	375312
GW441756 hydrochloride	IC50 > 4.5 µM	16219400
JNKIN7	IC50 > 4.5 µM	57340685
Purvalanol B	IC50 > 4.5 µM	448991	23254
BI2536	Kd = 4.7 µM	11364421	513909	22037378
Pazopanib	Kd = 4.7 µM	10113978	477772	22037378

Disease Linkage

General Disease Association:

Bone disorder and infectious disorder

Specific Diseases (Non-cancerous):

Cherubism (CRBM); Mycobacterium Abscessus

Comments:

Syk is a protein-tyrosine kinase that is widely expressed in hematopoietic cells, and is involved in coupling activated immunoreceptors that mediate diverse cellular responses.

Comments:

SYK appears to be an oncoprotein (OP) and a tumour suppressor protein (TSP). Syk is an oncoprotein in retinoblastoma, which is upregulated and is required for tumour cell survival. It is a potential tumour suppressor in human breast cancer. SYK is also an important regulator in acute myeloid leukemia.

Gene Expression in Cancers:

TranscriptoNET (www.transcriptonet.ca) analysis with mRNA expression data retrieved from the National Center for Biotechnology Information's Gene Expression Omnibus (GEO) database, which was normalized against 60 abundantly and commonly found proteins, indicated altered expression for this protein kinase as shown here as the percent change from normal tissue controls (%CFC) as supported with the Student T-test in the following types of human cancers: Breast epithelial carcinomas (%CFC= -69, p<0.0009); Classical Hodgkin lymphomas (%CFC= -74, p<0.001); Clear cell renal cell carcinomas (cRCC) stage I (%CFC= +419, p<0.003); and Ovary adenocarcinomas (%CFC= +93, p<0.021) The COSMIC website notes an up-regulated expression score for SYK in diverse human cancers of 294, which is 0.6-fold of the average score of 462 for the human protein kinases. The down-regulated expression score of 52 for this protein kinase in human cancers was 0.9-fold of the average score of 60 for the human protein kinases.

Mutagenesis Experiments:

Insertional mutagenesis studies in mice support a role for this protein kinase in mouse cancer oncogenesis.

Mutation Rate in All Cancers:

Percent mutation rates per 100 amino acids length in human cancers: 0.09 % in 25821 diverse cancer specimens. This rate is only 20 % higher than the average rate of 0.075 % calculated for human protein kinases in general.

Mutation Rate in Specific Cancers:

Highest percent mutation rates per 100 amino acids length in human cancers: 0.57 % in 805 skin cancers tested; 0.44 % in 1152 large intestine cancers tested; 0.29 % in 589 stomach cancers tested; 0.16 % in 1270 liver cancers tested; 0.13 % in 1941 lung cancers tested.

Frequency of Mutated Sites:

Most frequent mutations with the number of reports indicated in brackets: A330T (8).

Comments:

Only 2 deletions, 4 insertions, and no complex mutations are noted on the COSMIC website.

COSMIC Entry:

SYK

OMIM Entry:

600085

Nomenclature

Short Name:

Full Name:

Alias:

Classification

Type:

Group:

Family:

SubFamily:

Specific Links

General Links

Structure

Mol. Mass (Da):

# Amino Acids:

# mRNA Isoforms:

mRNA Isoforms:

4D Structure:

1D Structure:

3D Image (rendered using PV Viewer):

PDB ID

Subfamily Alignment

Domain Distribution:

Kinexus Products

hiddentext

Post-translation Modifications

Acetylated:

Serine phosphorylated:

Threonine phosphorylated:

Tyrosine phosphorylated:

Ubiquitinated:

Distribution

Human Tissue Distribution

% Max Expression: Mean Expression: Number of Samples: Standard Deviation:

% Max Expression: Mean Expression: Number of Samples: Standard Deviation:

Evolution

Species Conservation

PhosphoNET % Identity: PhosphoNET % Similarity: Homologene %Identity:

PhosphoNET % Identity: PhosphoNET % Similarity: Homologene %Identity:

Binding Proteins

hiddentext

Regulation

Activation:

Inhibition:

Synthesis:

Degradation:

Known Upstream Kinases

Based on in vitro and/or in vivo phosphorylation data

Known Downstream Substrates

Based on in vitro and/or in vivo phosphorylation data

Protein Kinase Specificity

Matrix Type:

Domain #:

Inhibitors

Based on in vitro and/or in vivo phosphorylation data

Disease Linkage

General Disease Association:

Specific Diseases (Non-cancerous):

Comments:

Comments:

Gene Expression in Cancers:

Mutagenesis Experiments:

Mutation Rate in All Cancers:

Mutation Rate in Specific Cancers:

Frequency of Mutated Sites:

Comments:

COSMIC Entry:

OMIM Entry:

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

% Max Expression:

Mean Expression:

Number of Samples:

Standard Deviation:

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:

PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity: